Kaushal Joins Aberdare Ventures

Aberdare Ventures said Tuesday that Mohit Kaushal has joined the firm as a partner. He will focus on Aberdare’s investments in technologies and services that will drive healthcare efficiency. Kaushal was most recently West Health’s chief strategy officer and EVP of business development.

PRESS RELEASE

Aberdare Ventures, a leading healthcare venture capital firm, today announced that Mohit Kaushal has joined the firm as a partner. Mohit (Mo) Kaushal is a leading authority on information-enabled care delivery and will focus on Aberdare’s investments in technologies and services that will drive healthcare efficiency.

“Mo has lived at the intersection of medicine, technology, communications, and policy for years,” noted Paul Klingenstein, founder of Aberdare Ventures. “He’ll make an enormous contribution to our efforts in transformational health investing. The timing is superb for all of us.”

An MD and MBA by training, Kaushal was most recently the inaugural Chief Strategy Officer and Executive Vice President of Business Development at West Health, a unique set of entities focused on lowering healthcare costs through medical research, healthcare policy, investment and entrepreneurship. He developed the West Health Investment Fund strategy, sourced and led investments in Humedica (acquired by Optum Health), Change Healthcare, RxAnte and goBalto.

Previously, Kaushal was the Director of Connected Health with the Federal Communications Commission, where he established the agency’s first dedicated healthcare team. During his time in the Obama administration, he was also a member of the White House Health IT task force, a cross-agency team focusing on implementing the technology aspects of Health Reform. Prior to this position, Kaushal was an investment professional at Polaris Venture Partners, and worked for Merrill Lynch’s Health Care Investment Banking Group and the World Health Organization. Kaushal holds an MBA from Stanford and an MD with distinction from Imperial College of Science, Technology and Medicine, London.

“Aberdare has a wonderful reputation for advancing some of the most disruptive companies in healthcare,” said Kaushal. “The team shares my passion for working with great companies and entrepreneurs to produce a much more efficient, consumer-centric and efficacious healthcare system, and I am very excited to be on board.”

Kaushal joins existing Aberdare Venture partners Paul Klingenstein, Darren Hite, Sami Hamade, Jake Odden, and Sigrid Van Bladel.

About Aberdare Ventures

Formed in 1999, Aberdare Ventures is a San Francisco-based venture capital firm investing in visionary entrepreneurs and technologies that are transforming healthcare with new biological, engineering, and information technologies. The firm has attracted and partnered with many superior early stage companies such as Ironwood, Pharmion, Clovis Oncology and MC10, repeatedly backing start-up’s that have grown to values exceeding $1 billion. The team of six investment professionals oversees a committed capital base in excess of $400 million in aggregate. For more information please visit: www.aberdare.com.